- WHO’s Technical Advisory Group has recommended the Emergency Use Listing status for Bharat Biotech’s COVID-19, Covaxin.
- Read Next: Ocugen Reverses Course From Monday’s Massive Surge As COVID-19 Vaccine Partner Faces WHO Setback.
- Ocugen Inc (NASDAQ:OCGN) is the U.S. partner for the India-made vaccine.
- The World Health Organization’s panel had last week sought additional clarifications from the firm.
- The Technical Advisory Group had met on October 26 and sought additional details from Bharat Biotech.
- Covaxin has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant.
- Related Link: Ocugen’s India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report.
- WHO’s approval will open travel channels to several countries that are yet to include Covaxin in their approved list of vaccines.
- Additionally, Covaxin has been granted an extension of shelf life for up to 12 months from the date of manufacture by India’s drug regulator.
- Covaxin initially had a shelf life of six months.
- Price Action: OCGN shares are down 4.47% at $14.98 during the market session on the last check Wednesday.
New Low-cost iPhone to Enter Mass Production in February
-Bloomberg https://www.bloomberg.com/news/articles/2020-01-21/new-low-cost-iphone-said-to-enter-mass-production-in-february?sref=V7uxlNge
